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Abstract
In the present study, we examined the relationships among cognitive function, magnetic resonance spectroscopy
(MRS) brain metabolite indices measured in the basal ganglia, and quantitative magnetic resonance imaging (MRI)
of the caudate nucleus and the putamen in the earliest stages of HIV-related cognitive involvement. Participants
included 22 HIV-positive individuals and 20 HIV-negative individuals. HIV-positive individuals performed
significantly more poorly than the HIV-negative individuals on several cognitive measures. In addition, the
choline0creatine ratio was significantly higher and the N-acetyl aspartate0choline ratio was significantly lower
among HIV patients. The caudate and putamen sizes were smaller among HIV-positive patients compared with
controls; however, the differences did not reach statistical significance. Correlation analyses revealed associations
between cognitive function and select MRS indices. In addition, caudate size was significantly correlated with
performances on higher-order thinking tests whereas putamen size was significantly correlated with performances
on motor tests. The results suggest that MRS differences are more pronounced than area size differences between
seropositive and seronegative individuals in mild stages of HIV-related cognitive impairment. However, basal
ganglia size remains an important contributor to cognitive status in this population. Longitudinal studies are needed
to determine the evolution of these imaging correlates of HIV-cognitive impairment in HIV.
(JINS, 2008, 14, 725–733.)
Keywords: MRS, Neuroimaging, Infection, Circuit, Subcortical, Brain

the introduction of ART, cognitive difficulties were most
frequently evident among individuals with significantly
depressed immune systems (Cohen et al., 2001; Selnes et al.,
1995). However, neuropathological data suggest that the
frequency of HIV-related encephalopathy may be increasing in the era of ART (Neuenburg et al., 2002).
Understanding the biomarkers associated with cognitive
dysfunction among HIV patients remains a pressing concern, especially given the observation that individuals with
HIV are now living longer, and cognitive difficulties are

INTRODUCTION
Despite the benefits afforded by antiretroviral therapy (ART),
the frequency of mild cognitive impairment among infected
individuals remains a significant concern for individuals
infected with human immunodeficiency virus (HIV). Before

Correspondence and reprint requests to: Robert Paul, University of
Missouri, St. Louis, Department of Psychology, One University Blvd.,
St. Louis, MO 63121-4400. E-mail: paulro@umsl.edu

725
Downloaded from https://www.cambridge.org/core. The Libraries - University of Missouri-St Louis, on 08 Apr 2019 at 20:24:08, subject to the Cambridge Core terms of use, available at
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1355617708080910

726
not entirely ameliorated with medical management of the
virus in the periphery (Brew, 2004; Sacktor et al., 1999,
2001). Furthermore, mild cognitive difficulties are associated with important activities of daily living. For example,
HIV patients with mild to moderate cognitive difficulties
exhibit impairments in shopping, cooking, financial management, driving performance and perceived quality of life
(Heaton et al., 2004; Marcotte et al., 2004; Osowiecki et al.,
2000). As such, it remains important to define the neural
signatures associated with cognitive difficulties in HIV.
Neuroimaging has offered significant insights into the
nature and extent of central nervous system (CNS) changes
associated with HIV infection, and the relationship between
these changes and cognitive function. In particular, brain
metabolite abnormalities measured by magnetic resonance
spectroscopy (MRS) are highly sensitive to central nervous
system involvement associated with HIV. Concentrations
of myoisonitol (MI) a marker of glial activity and N-acetylaspartate (NAA) a marker of mature neurons have received
the most attention in the research literature (for reviews see
Navia, 1997; Navia and Gonzalez, 1997; Tucker et al., 2004).
Abnormal levels of these metabolites have been reported
among asymptomatic patients (Meyerhoff et al., 1999; Tarasow et al., 2003), HIV patients with mild cognitive difficulties (Chang et al., 2004), and individuals with HIV-dementia
(Yiannoutsos et al., 2004). Increased MI and reduced NAA
have been identified most consistently in the subcortical
regions particularly the basal ganglia and the white matter,
with relative sparing of the cortex (Yiannoutsos et al., 2004).
Interestingly, there is some evidence that brain metabolite
abnormalities improve after initiating treatment with ART
(Chang et al., 1999), however, other data suggest that abnormalities may persist in the context of treatment (Chang et al.,
2003).
Studies frequently report MRS indices as ratios often
controlling for creatine (Cr) and choline (Cho), which are
believed to be relatively stable references, though this is
not a universally accepted approach. These metabolites represent a general energy metabolite (Cr) and a metabolite
associated with cell membrane synthesis (Cho). We recently
examined MRS ratios in a cohort of HIV-infected individuals with AIDS Dementia Classification scale scores ranging from 1 to 3 and reported significant relationships between
NAA0Cr in the frontal white matter and MI0Cr in the basal
ganglia with measures of gross and fine motor speed (Paul
et al., 2007). These findings were interpreted as evidence of
reduced neuronal integrity and increased gliosis among HIVinfected patients.
Similar to MRS indices, quantitative MRI metrics also
correlate with cognitive dysfunction associated with HIV
particularly in the more advanced stages of the disease (for
review, see Paul et al., 2002; Tucker et al., 2004). Structural
MRI abnormalities associated with HIV have been recognized since the beginning of the HIV epidemic, with cortical atrophy, reductions in caudate volume, and increased
white matter hyperintensities commonly reported (Aylward
et al., 1993, 1995; Dal Pan et al., 1992; Grant et al., 1987;
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Hestad et al., 1993). Of these findings, caudate volume has
emerged as a relatively consistent quantitative MRI variable associated with HIV cognitive status, particularly among
demented patients. Most studies have found significantly
reduced caudate volumes among HIV patients with dementia compared with healthy control subjects and nondemented HIV patients (see Paul et al., 2002). These findings
have typically been interpreted as reflecting the impact of
viral aggregation in the region of the basal ganglia, and the
subsequent interference in cortical-subcortical circuits
involved in cognitive operations.
Few studies have been directed at understanding the links
between basal ganglia regions other than the caudate and
cognitive performance in HIV. Presumably this reflects the
well recognized functional significance of the reciprocal
connections between the caudate and the dorsolateral prefrontal cortex, a system known to be involved in higherorder thinking and executive function (for review, see
Cummings, 1993). However, the putamen represents an additional structure of the basal ganglia, and the putamen has
reciprocal connections with the motor cortex (Romanelli
et al., 2005). Because reduction in psychomotor speed and
speeded fine motor dexterity are common symptoms of HIV,
there exists a theoretical rationale to support the involvement of the putamen in the expression of cognitive–motor
symptoms associated with HIV. Furthermore, recent work
by Moore et al. (2006) indicates that neuropathology within
the putamen (among other brain regions) correlates significantly with overall cognitive status among HIV patients.
These findings emphasize the importance of examining the
putamen using in vivo neuroimaging.
The studies conducted to date have identified the clinical utility of both MRS and quantitative MRI in the study
of HIV cognitive involvement. There have been few studies, however, that have examined the contribution of both
neuroimaging methods to cognitive status in the era of
ART, particularly in the early stages of HIV-related cognitive impairment. The purpose of the present study was to
examine the relationships between cognitive performance,
MRS and quantitative MRI among nondemented HIV
patients receiving ART. We predicted that HIV patients
would exhibit significant alterations in brain metabolites
measured in the basal ganglia and reduced caudate and
putamen sizes compared with seronegative individuals. We
also predicted that both MRS and quantitative MRI indices would correlate with cognitive performance among
the HIV patients but not the healthy control subjects.

METHODS
Subjects
Subjects for this study were selected from a largerAIDS Clinical Trials Group (ACTG)-sponsored trial of memantine on
cognitive function (ACTG 301). The parent study included
100 HIV-positive individuals and 20 HIV-negative individ-
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uals. The present study included a subset of HIV-positive
patients, for whom both MRI and MRS data were available
for analyses and for whom demographic variables were relatively well matched with seronegative control subjects.
Twenty-two individuals infected with HIV and enrolled in
an ACTG sponsored trial of memantine on cognitive function (ACTG 301) were included in the present study. Consistent with the parent study, HIV diagnosis was based on
serologic testing by ELISA and Western blot. Patients with a
psychiatric disorder other than depression were excluded. Individuals that met DSM-IV criteria for substance abuse or alcohol abuse within the 6 months before study enrollment were
excluded. Additional exclusionary criteria included developmental disorder, head injury, or neurologic disease. The
majority of HIV patients were currently taking ART. All data
reported in the present study were collected at the baseline
visit, before initiation of memantine.
The patients included 19 males and 3 females and the
sample averaged 37.9 (3.9) years of age. The median CD4
cell count was 341 (range 5 37–878). The patient group
included 6 individuals diagnosed with ADC stage 0 and 16
individuals diagnosed with ADC stage 1 (consistent with
mild cognitive impairment). Individuals with ADC stages 2
and 3 were excluded from the study.
Twenty healthy control subjects were included in the
present study. The healthy controls were required to meet
the same exclusion criteria as the HIV patients. The healthy
control subjects included 10 women and 9 men (sex was
not recorded for one subject), and the group averaged 34.7
(10.5) years of age. The HIV-positive individuals did not
differ from the HIV-negative individuals in terms of the
percentages of participants who completed less than 12 years
of education, high school, or more than 12 years of education ( p . .05).

Procedure
Participants completed demographic questionnaires, assessment of mood and neuropsychological evaluation in a single
testing session. Neuroimaging was subsequently conducted
within 2 weeks of the neuropsychological evaluation.All measures were administered and scored according to standard procedures. Participants received financial compensation for
participation in the study. Written informed consent was
obtained before enrollment. The protocol was approved by
local IRBs.

Mood
All individuals completed the Center for Epidemiologic Studies Depression Scale (CES-D) to quantify the severity of
mood disturbance. The CES-D is a 20-item self-report measure of mood that has been used extensively in HIV-related
research. Participants were asked to rate their agreement
with each question using a Likert Scale (1 5 rarely to 4 5
most of the time). Total score served as the dependent
measure.
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Magnetic resonance imaging
Neuroimaging was conducted using Signa 1.5 Tesla scanners (GE Medical Systems, Milwaukee, WI). Each system
operated with system 5.6 or higher and using a standard GE
head coil. Data were collected at six sites including Massachusetts General Hospital (MGH; the central site), University of California, Los Angeles (UCLA), University of
Pennsylvania, University of Washington, University of Rochester, Mt. Sinai Medical Center, University of Texas, and
University of California, San Francisco (UCSF). The imaging study protocol was directed and monitored by the central site (MGH). Initial MRS studies conducted by the
consortium revealed high consistency of MRS spectra across
the different imaging sites (Lee et al., 2003). T1-weighted
sagittal and high-resolution proton-density images were analyzed in this study. The sequence parameters were as follows: TR0TE 5 160600; FOV 5 20 cm; Slice thickness 5
3 mm; Matrix size 5 256 3 128, with 1 NEX. In addition, a
short echo-time (TE 5 35 ms) point-resolved spectroscopy
(PRESS) sequence was used for MRS data acquisition. The
voxel size was 2.0 3 2.0 3 1.5 cm 3 .

MRS
As described in detail previously (Lee et al., 2003), spectra
data were sampled in the basal ganglia with the voxel placed
in the putamen. Voxel placement verification was determined at the central processing site. We examined five MRS
variables obtained from the basal ganglia including MI0Cr,
NAA0Cr, Cho0Cr, NAA0Cho, and NAA0MI. These ratios
have been identified in previous studies as sensitive markers of neuronal injury in HIV (Lee et al., 2003). For this
study, we restricted our focus to the basal ganglia to retain
consistency with the quantitative MRI analyses. Raw data
were analyzed using a standardized protocol including a
commercial package (SageIDL; GE Medical Systems).
Images and raw spectroscopic data were transferred electronically to MGH for processing. All data were analyzed
using the commercial software package SageIDL (GE Medical Systems).

Quantitative MRI
We examined caudate and putamen size by means of manual tracing using NIH Image. For each nucleus, two slices
were selected, which represented the best anatomic images
of the caudate using the Matsui and Hirano atlas according
to a protocol described in detail elsewhere (Brickman et al.,
2003). Briefly, the left and right nuclei were traced twice
and the average of the measures was determined for each
slice. The two slices were then averaged to define an average area. All tracing was completed by a highly experienced neuromorphometrist who was blind to group status.
The dependent measures included area sizes for both nuclei.
Because we selected the average of two slices rather than
summed areas of multiple slices, the final dependent variable is identified as area size rather than volume.
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Neuropsychological assessment
Neuropsychological assessment was conducted by trained
research assistants at each site. The cognitive test battery
contained measures that have been demonstrated to be sensitive to HIV-related cognitive changes (Miller et al., 1990;
Sacktor et al., 2001). The individual measures are described
below.
Rey Auditory Verbal Learning Test (RAVLT; Rey, 1964):
The RAVLT was administered and scored according to standard methods. Specifically, participants were read a list of
words on five trials and were required to recall as many
words as possible on each trial. Following a brief delay
filled with a distractor list, participants were required to
recall as many words as possible from memory. The dependent measures were the total number of words recalled across
the five learning trials and the total number of words recalled
on the delay trial.
Timed Gait: Participants were instructed to walk as quickly
as possible for a distance of 10 meters. Three trials were
conducted and the dependent measure was the average time
for the three trials.
Grooved Pegboard (Klove, 1963): Participants completed the Grooved Pegboard task using the dominant and
nondominant hands on separate trials. All participants were
instructed to place the pegs into the grooved holes one-attime as quickly as possible using the designated hand. Time
to completion for each hand was the dependent variable. To
facilitate data reduction we included only the nondominant
hand as the final dependent variable for this study.
Stroop Color Word Interference Test (Comalli et al., 1962):
Participants were administered the Comalli modification of
the Stroop Test (Stroop, 1935). The test consisted of three
trials administered on three cards. On the first trial, participants were instructed to read aloud color words (e.g., blue)
printed in black ink. On the second trial participants were
presented with columns of blocks printed in colored ink,
and they were required to name the colors that the blocks
were printed in. On the final trial, participants were presented with color words printed in incongruent ink and they
were instructed to name the color that the words were printed
in. The dependent variable was time to complete each trial
one and trial 3. These two indices provide measures of processing speed and cognitive flexibility respectively.
Symbol Digit Task (Smith, 1973): Participants were
instructed to verbally substitute symbols with numbers using
a key held in constant view. Total correct within 90 seconds
was the dependent variable.
Trail Making (Anonymous, 1944): Consistent with standard administration, participants completed Trail Making A
and subsequently completed Trail Making B. On the former
task, participants were required to sequentially connect circled numbers using a pencil (e.g., 1-2-3-4 to 25). On the
latter task, participants were required to connect in ascending and alternating order, numbers and letters (e.g., 1-A2-B, etc). Time to completion was the dependent variable
on each task.
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CalCap (Miller, 1990; Miller et al., 1991): The California Computerized Assessment Package (CalCap) is a battery of attention and psychomotor tasks administered using
a computer. Two tests from the CalCap were recorded in the
parent study, including a test of simple reaction time and a
test of sequential reaction time. The test of simple reaction
time required participants to depress a key as soon as any
stimulus appeared on the computer screen. On the test of
sequential reaction time, participants were instructed to
depress the key when two numbers appear in sequential
order (e.g., the number 5 followed immediately by the number 5). The dependent variable for each test was the median
reaction time for correct responses.

Statistical analyses
Given the difference in male0female distribution between
the two groups, we conducted preliminary analyses among
the control sample to determine whether there were any
significant differences in MRI and MRS indices between
males and females. Results of independent t tests revealed
no statistically significant group differences in this group.
As such, sex was not entered as a covariate in subsequent
analyses. A single MANOVA was conducted to examine the
neuropsychological measures between groups. The neuropsychological measures included total correct on verbal
learning and delayed recall, average timed gait, time to completion for grooved pegboard (nondominant hand), Trail
Making A and B, Symbol Digit Test, and the incongruent
trial from the Comalli Stroop and simple reaction time and
sequential reaction time on the CalCap. Separate analyses
were conducted for the MRS and MRI imaging variables,
though all dependent measures for each modality were
included in each analysis to minimize spurious findings.
Univariate analyses were completed when the omnibus
MANOVA was statistically significant. Correlations were
conducted separately for each group to examine the degree
of variance shared between imaging variables and cognitive performance.

Results
The two groups did not differ significantly in age [t (39) 5
21.8; p . .05]. The HIV-positive individuals reported significantly more symptoms of depression compared with the
control subjects [t(37) 5 24.1); p , .01], however, the average CES-D score was 16, which falls just at the cutoff for
clinically meaningful depression. To determine whether
depression scores should be included as a covariate in subsequent analyses we conducted Pearson correlation analyses
between CES-D scores and all imaging and neuropsychological variables among the HIV-positive cohort. Results revealed
no significant associations between depression score and
imaging variables, and only one significant relationship
between depression score and neuropsychological performance (Trails B, r 5 0.55; p 5 .010). Given the lack of consistent relationships between these variables we did not include
depression as a covariate in the group comparisons.
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Neuropsychological Assessment of
Psychomotor Function and Attention

Table 2. Quantitative MRI indices and MRS metabolic
concentrations: Mean (SD)

A MANOVA was conducted to examine potential group
differences on measures of cognitive function (Table 1).
The omnibus MANOVA was significant between the groups
[F(11,27) 5 2.5, Wilks’ lambda 5 .49; p 5 .021]. Univariate contrasts revealed that the HIV-positive individuals performed significantly more poorly than the HIV-negative
individuals on Symbol Digit, Grooved pegboard nondominant hand, trials 1 and 3 of the Stroop, total recall and
delayed recall of the verbal memory test, both measures of
the CalCap test and timed gait. Group performance did not
differ on Trail Making A or Trail Making B tests.

MRS Brain Metabolite Levels
The overall MANOVA comparing brain metabolites between
groups was significant (Wilks’ lambda 5 .69(5,29) 5 2.5;
p 5 .48). Univariate contrasts revealed that HIV patients
had significantly higher levels of Cho0Cr ( p 5 .005) and
significantly lower levels of NAA0Cho ( p , .004) compared with the healthy control subjects (Table 2). The groups
did not differ on the levels of NAA0Cr, MI0Cr, or NAA0MI
in the basal ganglia ( ps . .05).

Quantitative MRI
The overall MANOVA for the area sizes was not statistically significant. As evident from Table 2, the mean sizes of
the caudate and putamen were lower for the HIV-positive
individuals compared with the HIV-negative individuals,
but the differences did not reach statistical significance.

Disease Factors
Neither plasma CD4 cell count nor plasma HIV RNA correlated significantly with putamen or caudate sizes or cognitive performances. However, plasma RNA correlated

Table 1. Neurocognitive performances: Mean (SD)
Measure

HIV patients

Healthy controls

Timed gait
Symbol Digit
Trail Making A
Simple reaction time0ms
Choice reaction time0ms
Pegboard–dominant hand
Stroop trial 1
Trail Making B
Stroop interference
Rey verbal learning
Rey delayed recall

10.7 (2.5)
48.8 (10.4)
29.0 (10.6)
462.6 (118.0)
605.4 (113.9)
69.3 (11.2)
73.3 (20.5)
77.3 (34.9)
134.2 (39.7)
46.3 (9.6)
8.8 (3.7)

9.4 (1.2)*
60.7 (12.0)*
28.0 (13.7)
389.8 (46.1)*
507.2 (78.0)*
58.2 (7.9)*
57.6 (10.3)*
58.3 (27.8)
102.3 (21.5)*
55.2 (7.1)*
12.3 (2.2)*

*p , .05.

Measure
Total putamen
Total caudate
NAA0Cr
Cho0Cr
NAA0Cho
NAA0MI
MI0Cr

HIV-positive
individuals

HIV-negative
individuals

1421.5 (212.1)
731.0 (106.6)
1.4 (.22)
.84 (.19)
1.7 (.26)
2.8 (.74)
.52 (.12)

1446.8 (193.7)
764.2 (78.8)
1.3 (.12)
.70 (.05)*
1.9 (.17)*
3.0 (.55)
.47 (.07)

*p , .05.

strongly with MI0Cr (r 5 0.68) and NAA0MI (r 5 20.59)
in the basal ganglia.

MRS, MRI, and Cognitive Correlational
Analyses
Correlational analyses of data from the HIV-positive group
revealed that specific brain metabolite levels were associated with aspects of cognitive performance. MI0Cr was
correlated with Trail Making A (r 5 .36; p 5 .14), choice
reaction time (r 5 0.42; p 5 .08), timed gait (r 5 0.43; p 5
.07) but the relationship met criteria for statistical significance only on Grooved Pegboard nondominant (r 5 0.59;
p 5 .010). NAA0MI was significantly associated with
Grooved Pegboard nondominant hand (r 5 0.59; p 5 .009)
and a trend was noted on trail making B (r 5 0.33; p 5 .17).
NAA0Cho was correlated with performance on nondominant Grooved Pegboard (r 5 20.63; p 5 .002). NAA0Cr
was not significantly related to the cognitive measures. By
comparison, analyses of the healthy controls revealed that
only NAA0Cho associated with cognitive performances,
with inverse relationships identified on Trail Making A (r 5
20.63; p 5 .034), Trail Making B (r 5 20.63; p 5 .004),
and Sequential Reaction Time (r 5 20.62; p 5 .006).
Relationships between MRI indices and cognition were
also significant for the HIV-positive group. Caudate area
size correlated significantly with Trail Making B (r 5 20.51;
p 5 .015), total learning across trials (r 5 0.52; p 5 .009),
trial 1 of the Stroop (r 5 0. 261; p 5 .003) timed gait (r 5
20.43; p 5 .04) and trial 3 of the Stroop (interference; r 5
20.52; p 5 .015). Putamen size correlated significantly
with Symbol digit (r 5 0.42; p 5 .046) and Grooved Pegboard dominant hand (r 5 20.44; p 5 .042). Among the
healthy controls, caudate size correlated with total learning
(r 5 0.53; p 5 .02), and putamen size correlated with Trail
Making A (r 5 20.71; p 5 .001), Trail Making B (r 5
20.54; p 5 .016), and Sequential Reaction Time (r 5 20.46;
p 5 .045). Putamen area size correlated significantly with
NAA0Cr in the basal ganglia (r 5 .44; p 5 .04), but no
other correlations between MRI and MRS indices were statistically significant.
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DISCUSSION
Results from the current study provide several important
contributions to the current literature. First, select MRS indices differed significantly between nondemented HIVpositive individuals on ART and demographically similar
seronegative control subjects. Second, both MRS and quantitative MRI indices were strongly related to cognitive function among the HIV patients. Collectively, the results suggest
that metabolite changes may be more pronounced than surface area changes among patients without dementia. However, some individuals may develop quantitative MRI
changes relatively early in the course of CNS disturbance
and these quantitative MRI changes correlate strongly with
specific cognitive functions.
The first observation that MRS abnormalities differed
significantly among nondemented individuals is consistent
with previous studies demonstrating the sensitivity of MRS
to CNS involvement in HIV. There is now a rich literature
describing significant brain metabolite changes associated
with HIV (for review, see Navia & Gonzalez, 1997; Navia
& Rostasy, 2005; Tucker et al., 2004). Significantly increased
levels of the purported glial markers MI and Cho are consistently observed in the subcortical brain regions, while
reductions in the neuronal marker NAA have been identified in the frontal white matter and subcortical grey matter.
In addition, MRS metabolite levels correlate with performance on select measures of cognitive function, including
tests of fine motor dexterity, executive function, and information processing speed (Chang et al., 1999; Meyerhoff
et al., 1999; Yiannoutsos et al., 2004). Cloak and colleagues
(2004) have also recently demonstrated that select MRS
metabolites map onto changes in the microstructural integrity of the brain in HIV as measured by diffusion tensor
imaging (DTI).
It is notable that the majority of patients in the present
study were taking ART, and as noted already studies have
reported improved cognitive function among HIV patients
following treatment with ART (Cohen et al., 2001; Robertson et al., 2004). Evidence that MRS abnormalities persist
despite treatment with ART suggests that the CNS compartment remains vulnerable in the context of long-term treatment. This is consistent with the results of an early small
study of patients before and after ART (Wilkinson et al.,
1997). In this study, patients exhibited reduced NAA0Cr in
the brain before treatment, suggestive of neuronal damage,
and this was followed by an increase in NAA0Cr following
initiation of ART, but a subsequent reduction in NAA0Cr
after prolonged treatment and the expression of cognitive
impairment. Collectively these findings suggest that ART
likely does not facilitate complete restoration of functional
systems to premorbid levels.
The second observation is in regard to the surface area
sizes of the putamen and the caudate. Several previous studies have reported significant atrophy of the caudate among
infected individuals, particularly among patients with dementia (Aylward et al., 1993, 1995; Stout et al., 1998). How-
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ever, not all studies have found relationships between HIV
infection, the expression of cognitive dysfunction, and caudate volume (e.g., Di Sclafani et al., 1997). In the present
study, we also did not observe significant reductions in caudate or putamen size at the group level, and this may reflect
the general health of our cohort.
While some caution is warranted in terms of taking too
much from our correlational findings, it is noteworthy that
caudate size correlated with cognitive function on multiple
measures, and the direction of the relationships was in the
predicted direction for each association (i.e., lower size associated with poorer performance). Of interest, caudate size
correlated most strongly with cognitive measures purportedly mediated by frontal–subcortical circuits, including Trail
Making A and B, total learning across trials and the Stroop.
By contrast, the area size of the putamen, which has anatomical connections to the motor cortex (Romanelli et al.,
2005) correlated more strongly with symbol digit and
grooved pegboard. These findings suggest a possible doubledissociation between the affected subcortical regions of the
brain and performance on tests of higher-order thinking
and psychomotor slowing in HIV.
It is important to recognize that several correlations were
conducted, and stringent controls for these correlations would
reduce the number of statistically significant relationships.
We elected not to enforce these constraints given the modest
size of the samples, but it is worth noting that adoption of a
threshold less than .01 would not have changed the general
direction of the findings with the exception of the correlations between putamen area size and performances on two
motor-based tests. Yet in both cases the effect size for these
correlations is large, and therefore the loss of significance
reflects power rather than limited association between the variables. As such, while caution is warranted in interpreting the
correlational analyses the results provide some support for
the differential relationship between these two nuclei and the
cognitive functions subserved by these neural systems in HIV.
Overall our results suggest that MRS changes are more
prominent than quantitative MRI changes in the early stages
of CNS involvement associated with HIV. However it is
important to note that in the absence of longitudinal data,
conclusions regarding the evolution of MRS vs. volumetric
abnormalities in HIV remain speculative. With that caveat
noted, our cross-sectional data suggests a model of CNS
involvement in HIV characterized by early metabolic effects
followed by changes in size within select subcortical gray
matter regions with advanced disease burden. It is possible
that cortical area changes also occur in the most advanced
stages of disease progression. This is not to suggest that the
cortical or subcortical regions are not impacted at a neuropathological level earlier in the process. Rather, these changes
may not be detected by quantitative MRI until much later in
the progression of the disease. Studies that examine cortical thinning on MRI in a healthy, treated sample would help
define this issue more clearly.
Future studies are also needed to determine whether the
expression of cognitive change and underlying MRI0MRS
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Fig. 1. Proposed model of the evolution of brain changes associated with HIV infection.

abnormalities evolves in a continuously linear manner as
indicated in Figure 1, and what viral and host factors increase
vulnerability to each stage in the process. Additional neuroimaging methods (e.g., functional MRI and DTI) may be
particularly useful to accomplish these goals in future studies. As an example, Cloak et al. (2004) recently demonstrated significant diffusion abnormalities among HIV
patients, and absolute MRS changes within these regions of
diffusion changes. Similar approaches using multiple imaging methodologies may reveal the neurobiological signatures associated with each stage of HIV CNS involvement.
It is important to note, however, that a recent study has
reported significant pathology in other regions of the brain
outside the caudate and other basal ganglia structures,
including the hippocampus (Moore et al., 2006). These
latter findings are interesting because they emphasize that
neuropathology in HIV is not restricted to the basal ganglia and the virus and associated inflammatory cascade
may involve medial temporal lobe structures known to be
important in cognitive operations. It is not clear, however,
what cognitive skills0circuits are most impacted by these
neuropathological findings, and0or whether the impact of
these brain abnormalities is moderated by age. Recent studies of cognitive impairment in HIV suggest that the pattern of deficits largely remains “subcortical” in nature in
this new era of chronic treatment (Lojek & Bornstein,
2005) but this may change with chronicity of the disease
and associated treatment as well as the advancing age of
the HIV population.
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